Pidotimod Immunomodulation for Psoriasis Efficacy and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis, both systemic and topical, face limitations in efficacy, safety, and the prevention of relapses, with existing medications often causing toxicity and requiring long-term use at high costs, while also being ineffective in managing severe manifestations like psoriatic arthritis and nail psoriasis.
Innovation Solution
The use of pidotimod, or its physiologically acceptable salts, administered systemically or topically, in various formulations to treat psoriasis, potentially combined with other active agents like immunosuppressive agents, Vitamin D analogues, and biologics, to attenuate skin and joint lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional systemic treatments (methotrexate, cyclosporine, corticosteroids) are used to treat psoriasis, then immune response is suppressed and skin lesions improve, but toxic effects increase and long-term use is required
Solution Approach 1:
The patent changes the immunomodulatory approach from broad immunosuppression to targeted immune response modulation. Pidotimod modifies the immune system's response parameters by enhancing endogenous protective mechanisms while suppressing pathological inflammation, achieving therapeutic effect with reduced toxicity compared to traditional immunosuppressants
Solution Approach 2:
Pidotimod acts as an immunomodulating intermediary substance that regulates the immune system's response to psoriasis. It mediates between the immune system's protective functions and pathological inflammatory responses, achieving balance without the severe side effects of direct immunosuppression
2Reliability
If biologic agents (monoclonal antibodies, etanercept, adalimumab) are used to treat severe psoriasis, then efficacy is improved, but treatment cost increases significantly and severe adverse events may occur
Solution Approach 1:
The patent employs pidotimod, a small molecule immunomodulator with favorable pharmacokinetics and lower cost compared to biologic agents. It provides effective treatment with a more favorable safety profile and reduced economic burden, serving as an alternative to expensive monoclonal antibodies
Solution Approach 2:
The patent shifts from high-cost biologic therapy to cost-effective immunomodulation with pidotimod. The drug achieves therapeutic results by modulating immune parameters rather than requiring expensive protein-based biologics, reducing both direct treatment cost and indirect economic burden
3Object-affected harmful factors
If topical treatments are used for localized psoriasis, then safety is improved and side effects are reduced, but treatment is limited to small body surface areas and cannot treat extra-skin manifestations
Solution Approach 1:
Pidotimod exhibits multi-functionality by effectively treating both cutaneous psoriasis and extra-skin manifestations such as psoriatic arthritis and nail psoriasis. A single systemic immunomodulatory agent addresses multiple disease manifestations, overcoming the limitations of topical treatments
4Duration of action of stationary object
If long-term treatment is required to maintain psoriasis remission, then relapse prevention is improved, but cumulative toxicity increases and patient compliance decreases
Solution Approach 1:
The patent enables periodic or intermittent treatment regimens with pidotimod, allowing patients to achieve and maintain remission with treatment cycles rather than continuous therapy. This reduces cumulative exposure and toxicity while maintaining effectiveness in preventing relapses
Data Source
AI summary
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat psoriasis. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either systemically or topically.